A Meta-Meta-Analysis: evaluation of Meta-Analyses Published in the effectiveness of cardiovascular comorbidities on the severity of COVID-19

Naeini, Mehri Bemani; Sahebi, Mahdieh; Nikbakht, Fateme; Jamshidi, Zahra; Ahmadimanesh, Mahnaz; Hashemi, Maryam; Ramezani, Javad; Miri, Hamid Heidarian; Yazdian-Robati, Rezvan

On January 2020, WHO confirmed the epidemic outbreak of SARS-CoV-2 as a Health Emergency of International Concern. The aim of this meta-meta-analysis is quantifying meta-analytic findings on the association of cardiovascular disease (CVD) comorbidities and COVID-19 severity. Findings suggest that chances of getting severe COVID-19 disease in patients with CVD is greater than those without CVD. Also, prevalence of CVD in patents with COVID-19 is 0.08 (95% CI =0.07-0.08). The OR as 3.44 indicates that the odds of getting severe COVID-19 is more than 3 times higher in those with CVD. Also, prevalence of hypertension in patient with COVID-19 is 0.27 (95%CI= 0.27-0.28) and the OR as 2.68 indicates that the odds of getting severe COVID-19 in cases with high blood pressure is more than 2.5 times higher than those without hypertension. It is rational to suppose that persons with coronary artery disease are prone to severe viral infection thereby, guideline-directed diagnosis and medical therapy is vital in CVD patients.